Virtu Financial LLC purchased a new stake in shares of Neos Therapeutics Inc (NASDAQ:NEOS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,259 shares of the company’s stock, valued at approximately $268,000. Virtu Financial LLC owned about 0.09% of Neos Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in NEOS. JPMorgan Chase & Co. purchased a new stake in shares of Neos Therapeutics during the third quarter valued at about $120,000. New York State Common Retirement Fund lifted its position in shares of Neos Therapeutics by 67.3% during the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after buying an additional 7,000 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Neos Therapeutics by 31.0% during the second quarter. Teachers Advisors LLC now owns 38,853 shares of the company’s stock valued at $284,000 after buying an additional 9,190 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Neos Therapeutics by 4.9% during the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock valued at $342,000 after buying an additional 2,168 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Neos Therapeutics by 14.1% during the third quarter. California State Teachers Retirement System now owns 38,915 shares of the company’s stock valued at $356,000 after buying an additional 4,800 shares during the last quarter. 49.33% of the stock is owned by institutional investors and hedge funds.
Several analysts have commented on the stock. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research report on Thursday. BidaskClub raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 10th. BMO Capital Markets lowered shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $14.00.
Neos Therapeutics Inc (NEOS) opened at $8.85 on Friday. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42. Neos Therapeutics Inc has a 1 year low of $6.30 and a 1 year high of $13.15.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. The firm had revenue of $7.79 million during the quarter, compared to analyst estimates of $9.30 million. Neos Therapeutics had a negative net margin of 264.80% and a negative return on equity of 377.69%. equities analysts expect that Neos Therapeutics Inc will post -1.65 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Virtu Financial LLC Takes Position in Neos Therapeutics Inc (NEOS)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/17/virtu-financial-llc-takes-position-in-neos-therapeutics-inc-neos.html.
Neos Therapeutics Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.